DE602004018622D1 - Pharmazeutische zusammensetzung enthaltend 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylessigsäure - Google Patents

Pharmazeutische zusammensetzung enthaltend 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylessigsäure

Info

Publication number
DE602004018622D1
DE602004018622D1 DE602004018622T DE602004018622T DE602004018622D1 DE 602004018622 D1 DE602004018622 D1 DE 602004018622D1 DE 602004018622 T DE602004018622 T DE 602004018622T DE 602004018622 T DE602004018622 T DE 602004018622T DE 602004018622 D1 DE602004018622 D1 DE 602004018622D1
Authority
DE
Germany
Prior art keywords
fluoroanilino
chloro
methyl
pharmaceutical composition
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004018622T
Other languages
English (en)
Inventor
Patrick Forenzo
Maha Y Khaled
Barbara Wang
Joseph Lawrence Zielinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32990870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004018622(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602004018622D1 publication Critical patent/DE602004018622D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE602004018622T 2003-03-12 2004-03-11 Pharmazeutische zusammensetzung enthaltend 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylessigsäure Expired - Lifetime DE602004018622D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45414503P 2003-03-12 2003-03-12
PCT/EP2004/002528 WO2004080451A1 (en) 2003-03-12 2004-03-11 Pharmaceutical composition comprising 5-methyl-2-2’-(chloro-6’-fluoroanilino) phe nylacetic acid

Publications (1)

Publication Number Publication Date
DE602004018622D1 true DE602004018622D1 (de) 2009-02-05

Family

ID=32990870

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004018622T Expired - Lifetime DE602004018622D1 (de) 2003-03-12 2004-03-11 Pharmazeutische zusammensetzung enthaltend 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylessigsäure

Country Status (30)

Country Link
US (2) US20060094787A1 (de)
EP (1) EP1603550B1 (de)
JP (1) JP4580921B2 (de)
KR (1) KR20050109077A (de)
CN (1) CN100345536C (de)
AR (1) AR043536A1 (de)
AT (1) ATE418332T1 (de)
AU (1) AU2004218921B2 (de)
BR (1) BRPI0408270A (de)
CA (1) CA2518393A1 (de)
CL (1) CL2004000496A1 (de)
DE (1) DE602004018622D1 (de)
EC (1) ECSP055998A (de)
ES (1) ES2318277T3 (de)
HK (1) HK1086492A1 (de)
HR (1) HRP20050787A2 (de)
IL (1) IL170518A (de)
IS (1) IS2658B (de)
MA (1) MA27670A1 (de)
MX (1) MXPA05009686A (de)
MY (1) MY139455A (de)
NO (1) NO20054662L (de)
NZ (1) NZ542218A (de)
PE (1) PE20041063A1 (de)
PT (1) PT1603550E (de)
RU (1) RU2363462C2 (de)
TN (1) TNSN05222A1 (de)
TW (1) TWI327913B (de)
WO (1) WO2004080451A1 (de)
ZA (1) ZA200506750B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415111A (pt) * 2003-10-08 2006-11-28 Novartis Ag composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético
KR100900915B1 (ko) * 2007-05-07 2009-06-05 이연제약주식회사 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
US20100267787A1 (en) * 2007-11-12 2010-10-21 Gregory Harasymiw Pharmaceutical Compositions
EP2926810A1 (de) * 2014-03-31 2015-10-07 Sanovel Ilac Sanayi ve Ticaret A.S. Orale flüssige pharmazeutische formulierungen von loxoprofen
CA3027434A1 (en) 2016-06-16 2017-12-21 Cutispharma, Inc. Composition and method for proton pump inhibitor suspension
EP3509592A4 (de) 2016-09-09 2020-07-22 Cutispharma, Inc. Suspensionen und verdünnungsmittel für metronidazol und baclofen
EP3655418A4 (de) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. Verfahren zur behandlung von glioblastom
US11628144B2 (en) 2017-09-29 2023-04-18 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5840768A (en) * 1997-06-04 1998-11-24 Fmc Corporation MCC: alginate pharmaceutical suspensions
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
BR0306777A (pt) * 2002-01-07 2005-04-26 Pharmacia Corp Tratamento de dor, inflamação e distúrbios relacionados à inflamação, com uma combinação de um inibidor seletivo de ciclooxigenase-2 e aspirina
US20030203915A1 (en) * 2002-04-05 2003-10-30 Xinqin Fang Nitric oxide donors, compositions and methods of use related applications

Also Published As

Publication number Publication date
NO20054662L (no) 2005-12-05
PE20041063A1 (es) 2005-03-07
IS8049A (is) 2005-09-28
RU2363462C2 (ru) 2009-08-10
ATE418332T1 (de) 2009-01-15
PT1603550E (pt) 2009-03-20
TWI327913B (en) 2010-08-01
IS2658B (is) 2010-08-15
HK1086492A1 (en) 2006-09-22
ES2318277T3 (es) 2009-05-01
EP1603550A1 (de) 2005-12-14
EP1603550B1 (de) 2008-12-24
US20060094787A1 (en) 2006-05-04
AR043536A1 (es) 2005-08-03
TW200505429A (en) 2005-02-16
BRPI0408270A (pt) 2006-03-07
US20090048344A1 (en) 2009-02-19
JP4580921B2 (ja) 2010-11-17
HRP20050787A2 (en) 2006-12-31
MXPA05009686A (es) 2005-10-20
TNSN05222A1 (en) 2007-06-11
AU2004218921A1 (en) 2004-09-23
CA2518393A1 (en) 2004-09-23
CL2004000496A1 (es) 2005-01-14
MA27670A1 (fr) 2005-12-01
JP2006519811A (ja) 2006-08-31
MY139455A (en) 2009-10-30
ZA200506750B (en) 2007-02-28
NO20054662D0 (no) 2005-10-11
AU2004218921B2 (en) 2007-05-17
CN100345536C (zh) 2007-10-31
ECSP055998A (es) 2006-01-27
NZ542218A (en) 2009-01-31
KR20050109077A (ko) 2005-11-17
WO2004080451A1 (en) 2004-09-23
CN1756541A (zh) 2006-04-05
IL170518A (en) 2010-11-30
RU2005131310A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
ATE317260T1 (de) Pharmazeutische formulierungen mit platinderivaten
DK1660104T3 (da) Farmaceutisk formulering indeholdende lanthanforbindelser
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
NO20054662D0 (no) Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre
PT1501534E (pt) Formulacoes farmaceuticas
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
DE60142197D1 (de) Pharmazeutische Zusammensetzung
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DE60332393D1 (de) Flüssige pharmazeutische zusammensetzung mit pyridonderivaten
ATE320807T1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
DE60317803D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung
DK1587478T3 (da) Farmaceutisk sammensætning
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE366128T1 (de) Pharmazeutische zusammensetzung
ATE507831T1 (de) Melatonin enthaltende pharmazeutische formulierung
ATE332690T1 (de) Perindopril enthaltende pharmazeutische zusammensetzung mit oraler dispersion
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE502004003170D1 (de) Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure
DE10107261B4 (de) Pharmazeutische Zusammensetzung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN